An observational study in Breast Cancer, sponsored by Korea University Ansan Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 27 Years to 86 Years. Per ClinicalTrials.gov, last updated 2023-10-27.
Sponsored by Korea University Ansan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.
Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 68th largest by enrollment of the 109 observational ones that give a count, is one of 43 that started in 2021, is one of 110 observational ones, and was the 505th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Korea, Republic of, United States, Belgium and 5 more countries
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+ · Women only
AstraZeneca · Sites in Korea, Republic of, United States, France and 6 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Canada and 6 more countries
Ages 18+
BeOne Medicines · Sites in Korea, Republic of, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 27 Years to 86 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
618 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 104 · Phase 2 182 · Phase 3 177 · Phase 4 14
First in 2001; this study’s year is marked. 43 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 218 across the 505 interventional studies, 444 across the 109 observational. Of the 304 that completed or were terminated, 148 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
348 of 618 have an industry lead sponsor. The 10 most frequent:
Korea University Ansan Hospital is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Korea University Ansan Hospital has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
44 of the studies in Breast Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 14 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT05440149Phase 3Seoul National University HospitalThe Postoperative Radiotherapy in N1 Breast Cancer Patients | 2026-12-31 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 44 to your calendar (.ics) → With an account.
Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective study is to investigate the performance of ultrafast MRI radiomics in classifying histological factors and subtypes of breast cancer compared with standard MRI among radiologists with varying experience. The written informed consent was obtained from all participant. We extracted 1618 radiomic features from ultrafast and standard contrast-enhanced MRI before treatment. Classification of hormonal receptors, human epidermal growth factor receptor 2, and Ki67 status and subtypes was evaluated using the area under the receiver-operating characteristic curve (AUC) with the DeLong test.
The study population should fulfill the following criteria as follows:(a) histologically confirmed invasive breast cancer, (b) participant consent, and (c) MRI performed before treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MRI based classification of breast cancer histological factors and subtypes
The signal intensity of MRI according to histological factors and subtypes of breast cancer
Quantitative image values obtained from ultrafast MRI show similar performance in classifying histological factors and subtypes compared with standard MRI.
Time frame: Baseline, pre-surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Nov 2022, 13 months.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 13 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University Ansan Hospital